GSE200291

Effect of anti-TNF/IL-6 NANOBODY® VHH, Humira, Sylvant, TNF, IL6 and TNF+IL6 in RA-FLS/T cell cocultures

Whole-study status Not suitable

Dataset does not meet the current suitability threshold.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

71 case / 27 control samples elsewhere in the study have incomplete or conflicting evidence; they are not included above

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Source
GEO
Assay
bulk RNA-seq
Organism
Homo sapiens
Whole-study samples
98 samples
Specimen
Biofluid
Reported/interpreted study design
Treatment vs control Design classification does not establish patient pairs.
Comparison type
Tumor vs normal
Contributors
Biesemann N, Margerie D
Contact name
Daniel Margerie
Submission date
2022-04-06
Last update
2022-12-31
Organization
Sanofi-Aventis Deutschland GmbH
Department
R&D, Digital Data Sciences
Public date
2022-12-31
Experiment types
Expression profiling by high throughput sequencing
Platforms
GPL24676 Illumina NovaSeq 6000 (Homo sapiens)
Series type
SubSeries
SubSeries
Not available
BioProject
PRJNA824011

Summary

Additive effects of TNF and IL-6 were evaluated in cell-based model for rheumatoid arthritis (RA) and then compared to treatment with anti-TNF/IL-6 NANOBODY® VHH, Humira and Sylvant by RNA-seq

Overall design

Fibroblast-like synoviocytes from RA donors (RA-FLS, Cell Applications, Inc.) were cocultured with CD4 T cells from healthy human donors (n=9, 3 RA-FLS donors combined with 3 different CD4 T cell donors). PBMC’s were isolated from whole blood using Ficoll-Paque (GE Healthcare). CD4 T cells were purified from PBMCs by negative selection (Milteny Biotec) and directly added to attached RA-FLS in a 10:1 ratio (CD4: RA-FLS). Additive effects of TNF and IL-6 were evaluated by stimulating RA-FLS/T cell coculture with recombinant TNF (Sigma), IL-6/sIL-6R (R&D) or a combination. Similar experiments were performed with clinically approved anti-TNF and anti-IL-6 antibodies (Humira and Sylvant, from pharmacy), their combination and our bispecific anti-TNF/IL-6 NANOBODY® VHH after stimulation with 100ng/ml recombinant IL-17A, sIL-6R (R&D) and anti-CD3 (Biolegend). For these experiments, antibodies were compared to IgG1 isotype control, while anti-TNF/IL-6 NANOBODY® VHH was compared to a NANOBODY isotype control.

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
98 GSM samples
 Primary source
recount3

Planned trusted source for processed count availability.

 No match found
Expression Atlas

Planned source for curated expression experiment links.

 No match found
PubMed

Publication context when PubMed identifiers are already known.

 No match found

Metadata Quality Components

Persisted metadata quality

100 pts
Clarity
100%
Weight
100 pts

Sample source clarity: All samples have source metadata and clear GSE/GSM accessions. Group clarity: Rule-based grouping found both case and control samples. Disease clarity: Disease or condition metadata normalized. Tissue clarity: Anatomical source metadata normalized. Treatment clarity: Treatment status metadata normalized where treatment is part of the comparison. Replicate clarity: No pooled sample or technical replicate flags detected. Data availability clarity: Dataset-level processed or raw data availability is explicit.

Analysis Readiness

Review before analysis
85% DE readiness

Contrast completeness

25/25 pts

Both case and control groups are present in the proposed grouping.

Minimum group size

20/20 pts

Each contrast group has at least 2 samples.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

3/15 pts

Unassigned or review-needed samples remain before analysis.

Blocking warnings

7/10 pts

Warnings are present, but none are critical blockers.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

  • 9 samples need manual grouping review.

Next Steps

  • Resolve unassigned or review-needed samples in the grouping table.

Analysis Preparation Checklist

4/6 ready

Group labels reviewed

Needs review

Siftome proposed case and control labels, but no reviewer confirmation is stored yet.

Open the sample grouping CSV and confirm group labels before analysis.

Minimum sample count met

Ready

Both groups meet the minimum of 2 samples.

Confirm whether the cohort is large enough for the intended statistical analysis.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Needs review

9 review-needed samples and 0 unassigned samples remain.

Resolve ambiguous and unassigned samples before finalizing the contrast.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Bioinformatician review required

Ask a bioinformatician to review grouping, count availability, exclusions, and design before DE.

Analysis readiness has blockers that must be resolved before DE.

One or more samples were flagged for manual review.

Why This Is Ranked Here

Tumor vs normal
Not suitable Dataset does not meet the current suitability threshold.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Disease context Rheumatoid arthritis Disease context came from Normalization rules.
  • Likely case group Treated 71 samples
  • Likely control group Untreated 27 samples

Intent Interpretation

  • Downgrade or exclusion reason Downgraded for tissue search because it is a biofluid cohort. Derived from current-intent ranking reasons.

Ranking Facts

Supporting evidence

  • Comparison: Treatment vs control. Specimen: Biofluid. Comparison suitability: 0%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Interpreted disease metadata: Rheumatoid arthritis.
  • Processed data is available for downstream review.

Cautions

  • Downgraded for tissue search because it is a biofluid cohort.
  • Downgraded for tissue search because it is a treatment/control experiment.
  • Treatment/control experiment downgraded because this ranking targets tumor-vs-normal tissue comparisons.
  • Blood, plasma, or serum cohort downgraded because this ranking targets tissue tumor-vs-normal comparisons.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Dataset Warnings

Normalized Fields

316 fields

Sample Group Preview

showing 77 of 98 preview rows Show Hide
Study totals: Case 71 | Control 27 | Unassigned 0 | Excluded 0 | Ambiguous 0 showing 77 of 98 preview rows
Group Role Accession Title Source / characteristics Reason
Treated Case GSM6030350 8808R2_002_IndexUDI0002_TTATAACC+GATATCGA_L003_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Stimulated treated sample: Treated sample may need exclusion outside treatment comparisons.
Treated Case GSM6030353 8808R2_005_IndexUDI0005_ATCCACTG+AGGTGCGT_L003_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Anti-TNF mAb Explicit characteristic comparison arm detected.
Treated Case GSM6030354 8808R2_006_IndexUDI0006_GCTTGTCA+GAACATAC_L003_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Anti-IL-6 mAb Explicit characteristic comparison arm detected.
Treated Case GSM6030355 8808R2_007_IndexUDI0007_CAAGCTAG+ACATAGCG_L003_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Anti-TNF +anti-IL-6 mAb Explicit characteristic comparison arm detected.
Treated Case GSM6030356 8808R2_010_IndexUDI0010_GACCTGAA+TTGGTGAG_L003_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Anti-TNF/IL-6 NANOBODY® VHH Explicit characteristic comparison arm detected.
Treated Case GSM6030357 8808R2_012_IndexUDI0012_CTCTCGTC+TATAACCT_L003_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Recombinant hTNFa Explicit characteristic comparison arm detected.
Treated Case GSM6030358 8808R2_013_IndexUDI0013_CCAAGTCT+AAGGATGA_L003_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Recombinant hIL-6 Explicit characteristic comparison arm detected.
Treated Case GSM6030359 8808R2_014_IndexUDI0014_TTGGACTC+GGAAGCAG_L003_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Recombinant hTNFa + hIL-6 Explicit characteristic comparison arm detected.
Treated Case GSM6030361 8808R2_044_IndexUDI0016_AATCCGGA+CTACAGTT_L003_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Stimulated treated sample: Treated sample may need exclusion outside treatment comparisons.
Treated Case GSM6030364 8808R2_047_IndexUDI0019_ATGTAAGT+ACTCTATG_L003_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Anti-TNF mAb Explicit characteristic comparison arm detected.
Treated Case GSM6030365 8808R2_048_IndexUDI0020_GCACGGAC+GTCTCGCA_L003_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Anti-IL-6 mAb Explicit characteristic comparison arm detected.
Treated Case GSM6030366 8808R2_049_IndexUDI0021_GGTACCTT+AAGACGTC_L003_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Anti-TNF +anti-IL-6 mAb Explicit characteristic comparison arm detected.
Treated Case GSM6030367 8808R2_052_IndexUDI0024_ATGAGGCC+GTTAATTG_L003_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Anti-TNF/IL-6 NANOBODY® VHH Explicit characteristic comparison arm detected.
Treated Case GSM6030368 8808R2_054_IndexUDI0026_GTCGGAGC+GGTTATAA_L003_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Recombinant hTNFa Explicit characteristic comparison arm detected.
Treated Case GSM6030369 8808R2_055_IndexUDI0027_CTTGGTAT+CCAAGTCC_L003_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Recombinant hIL-6 Explicit characteristic comparison arm detected.
Treated Case GSM6030370 8808R2_056_IndexUDI0028_TCCAACGC+TTGGACTT_L003_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Recombinant hTNFa + hIL-6 Explicit characteristic comparison arm detected.
Treated Case GSM6030372 8808R2_086_IndexUDI0030_TTACAGGA+TGACAAGC_L003_001 RA-FLS and T-cells Fls donor: D3; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Stimulated treated sample: Treated sample may need exclusion outside treatment comparisons.
Treated Case GSM6030375 8808R2_089_IndexUDI0033_TACCGAGG+CCTGAACT_L003_001 RA-FLS and T-cells Fls donor: D3; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Anti-TNF mAb Explicit characteristic comparison arm detected.
Treated Case GSM6030376 8808R2_090_IndexUDI0034_CGTTAGAA+TTCAGGTC_L003_001 RA-FLS and T-cells Fls donor: D3; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Anti-IL-6 mAb Explicit characteristic comparison arm detected.
Treated Case GSM6030377 8808R2_091_IndexUDI0035_AGCCTCAT+AGTAGAGA_L003_001 RA-FLS and T-cells Fls donor: D3; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Anti-TNF +anti-IL-6 mAb Explicit characteristic comparison arm detected.
Treated Case GSM6030378 8808R2_094_IndexUDI0038_CTACGACA+GAGTCCAA_L003_001 RA-FLS and T-cells Fls donor: D3; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Anti-TNF/IL-6 NANOBODY® VHH Explicit characteristic comparison arm detected.
Treated Case GSM6030379 8808R2_096_IndexUDI0040_CGGACAAC+TCCGGATT_L003_001 RA-FLS and T-cells Fls donor: D3; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Recombinant hTNFa Explicit characteristic comparison arm detected.
Treated Case GSM6030380 8808R2_097_IndexUDI0041_ATATGGAT+CTGTATTA_L003_001 RA-FLS and T-cells Fls donor: D3; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Recombinant hIL-6 Explicit characteristic comparison arm detected.
Treated Case GSM6030381 8808R2_098_IndexUDI0042_GCGCAAGC+TCACGCCG_L003_001 RA-FLS and T-cells Fls donor: D3; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Recombinant hTNFa + hIL-6 Explicit characteristic comparison arm detected.
Treated Case GSM6030383 8808R2_142_IndexUDI0044_GGAGCGTC+GTCCGTGC_L003_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Stimulated treated sample: Treated sample may need exclusion outside treatment comparisons.
Treated Case GSM6030386 8808R2_145_IndexUDI0047_GTTCCAAT+AATTCTGC_L003_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Anti-TNF mAb Explicit characteristic comparison arm detected.
Treated Case GSM6030387 8808R2_146_IndexUDI0048_ACCTTGGC+GGCCTCAT_L003_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Anti-IL-6 mAb Explicit characteristic comparison arm detected.
Treated Case GSM6030388 8808R2_147_IndexUDI0049_ATATCTCG+ATCTTAGT_L003_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Anti-TNF +anti-IL-6 mAb Explicit characteristic comparison arm detected.
Treated Case GSM6030389 8808R2_150_IndexUDI0052_GGTGAACC+GCGTTGGA_L003_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Anti-TNF/IL-6 NANOBODY® VHH Explicit characteristic comparison arm detected.
Treated Case GSM6030390 8808R2_152_IndexUDI0054_TGGTGGCA+TCCTGTAA_L003_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Recombinant hTNFa Explicit characteristic comparison arm detected.
Treated Case GSM6030391 8808R2_153_IndexUDI0055_AGGCAGAG+AGAATGCC_L001_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Recombinant hIL-6 Explicit characteristic comparison arm detected.
Treated Case GSM6030392 8808R2_154_IndexUDI0056_GAATGAGA+GAGGCATT_L003_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Recombinant hTNFa + hIL-6 Explicit characteristic comparison arm detected.
Treated Case GSM6030394 8808R2_156_IndexUDI0058_CATAATAC+TTCTAACG_L004_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Stimulated treated sample: Treated sample may need exclusion outside treatment comparisons.
Treated Case GSM6030397 8808R2_159_IndexUDI0061_CGGAACTG+CACTACGA_L004_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Anti-TNF mAb Explicit characteristic comparison arm detected.
Treated Case GSM6030398 8808R2_161_IndexUDI0063_TTGCCTAG+ACCACTTA_L004_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Anti-TNF +anti-IL-6 mAb Explicit characteristic comparison arm detected.
Treated Case GSM6030399 8808R2_164_IndexUDI0066_GTGTCGGA+GCTTGCGC_L004_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Anti-TNF/IL-6 NANOBODY® VHH Explicit characteristic comparison arm detected.
Treated Case GSM6030400 8808R2_166_IndexUDI0068_CCTTCACC+GACGCTCC_L004_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Recombinant hTNFa Explicit characteristic comparison arm detected.
Treated Case GSM6030401 8808R2_167_IndexUDI0069_GCCACAGG+CATGCCAT_L004_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Recombinant hIL-6 Explicit characteristic comparison arm detected.
Treated Case GSM6030402 8808R2_168_IndexUDI0070_ATTGTGAA+TGCATTGC_L004_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Recombinant hTNFa + hIL-6 Explicit characteristic comparison arm detected.
Treated Case GSM6030404 8808R2_198_IndexUDI0072_GTCTACAC+GCCAAGGT_L004_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Stimulated treated sample: Treated sample may need exclusion outside treatment comparisons.
Treated Case GSM6030407 8808R2_201_IndexUDI0075_AGTACTCC+AACCTGTT_L004_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Anti-TNF mAb Explicit characteristic comparison arm detected.
Treated Case GSM6030408 8808R2_202_IndexUDI0076_GACGTCTT+GGTTCACC_L004_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Anti-IL-6 mAb Explicit characteristic comparison arm detected.
Treated Case GSM6030409 8808R2_203_IndexUDI0077_TGCGAGAC+CATTGTTG_L004_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Anti-TNF +anti-IL-6 mAb Explicit characteristic comparison arm detected.
Treated Case GSM6030410 8808R2_206_IndexUDI0080_GTGAATAT+TCTCATTC_L004_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Anti-TNF/IL-6 NANOBODY® VHH Explicit characteristic comparison arm detected.
Treated Case GSM6030411 8808R2_208_IndexUDI0082_GGTCACGA+GTATTATG_L004_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Recombinant hTNFa Explicit characteristic comparison arm detected.
Treated Case GSM6030412 8808R2_209_IndexUDI0083_CTGCTTCC+GATAGATC_L004_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Recombinant hIL-6 Explicit characteristic comparison arm detected.
Treated Case GSM6030413 8808R2_210_IndexUDI0084_TCATCCTT+AGCGAGCT_L004_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Recombinant hTNFa + hIL-6 Explicit characteristic comparison arm detected.
Treated Case GSM6030415 8808R2_212_IndexUDI0086_GAACCGCG+TGACCTTA_L004_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D3; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Stimulated treated sample: Treated sample may need exclusion outside treatment comparisons.
Treated Case GSM6030418 8808R2_215_IndexUDI0089_TATCGCAC+CTTAGTGT_L004_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D3; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Anti-TNF mAb Explicit characteristic comparison arm detected.
Treated Case GSM6030419 8808R2_216_IndexUDI0090_CGCTATGT+TCCGACAC_L004_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D3; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Anti-IL-6 mAb Explicit characteristic comparison arm detected.
21 additional case samples are hidden from this preview.
Untreated Control GSM6030349 8808R2_001_IndexUDI0001_CCGCGGTT+AGCGCTAG_L003_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Unstimulated Treatment control marker detected.
Control Control GSM6030351 8808R2_003_IndexUDI0003_GGACTTGG+CGCAGACG_L003_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: IgG1 isotype control Explicit characteristic control arm detected.
Control Control GSM6030352 8808R2_004_IndexUDI0004_AAGTCCAA+TATGAGTA_L003_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: NANOBODY® isotype control Explicit characteristic control arm detected.
Untreated Control GSM6030360 8808R2_043_IndexUDI0015_GGCTTAAG+TCGTGACC_L003_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Unstimulated Treatment control marker detected.
Control Control GSM6030362 8808R2_045_IndexUDI0017_TAATACAG+ATATTCAC_L003_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: IgG1 isotype control Explicit characteristic control arm detected.
Control Control GSM6030363 8808R2_046_IndexUDI0018_CGGCGTGA+GCGCCTGT_L003_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: NANOBODY® isotype control Explicit characteristic control arm detected.
Untreated Control GSM6030371 8808R2_085_IndexUDI0029_CCGTGAAG+CAGTGGAT_L003_001 RA-FLS and T-cells Fls donor: D3; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Unstimulated Treatment control marker detected.
Control Control GSM6030373 8808R2_087_IndexUDI0031_GGCATTCT+CTAGCTTG_L003_001 RA-FLS and T-cells Fls donor: D3; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: IgG1 isotype control Explicit characteristic control arm detected.
Control Control GSM6030374 8808R2_088_IndexUDI0032_AATGCCTC+TCGATCCA_L003_001 RA-FLS and T-cells Fls donor: D3; Blood t-cell donor: D1; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: NANOBODY® isotype control Explicit characteristic control arm detected.
Untreated Control GSM6030382 8808R2_141_IndexUDI0043_AAGATACT+ACTTACAT_L003_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Unstimulated Treatment control marker detected.
Control Control GSM6030384 8808R2_143_IndexUDI0045_ATGGCATG+AAGGTACC_L003_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: IgG1 isotype control Explicit characteristic control arm detected.
Control Control GSM6030385 8808R2_144_IndexUDI0046_GCAATGCA+GGAACGTT_L003_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: NANOBODY® isotype control Explicit characteristic control arm detected.
Untreated Control GSM6030393 8808R2_155_IndexUDI0057_TGCGGCGT+CCTCGGTA_L003_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Unstimulated Treatment control marker detected.
Control Control GSM6030395 8808R2_157_IndexUDI0059_GATCTATC+ATGAGGCT_L004_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: IgG1 isotype control Explicit characteristic control arm detected.
Control Control GSM6030396 8808R2_158_IndexUDI0060_AGCTCGCT+GCAGAATC_L004_001 RA-FLS and T-cells Fls donor: D1; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: NANOBODY® isotype control Explicit characteristic control arm detected.
Untreated Control GSM6030403 8808R2_197_IndexUDI0071_ACTCGTGT+ATTGGAAC_L004_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Unstimulated Treatment control marker detected.
Control Control GSM6030405 8808R2_199_IndexUDI0073_CAATTAAC+CGAGATAT_L004_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: IgG1 isotype control Explicit characteristic control arm detected.
Control Control GSM6030406 8808R2_200_IndexUDI0074_TGGCCGGT+TAGAGCGC_L004_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D2; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: NANOBODY® isotype control Explicit characteristic control arm detected.
Untreated Control GSM6030414 8808R2_211_IndexUDI0085_AGGTTATA+CAGTTCCG_L004_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D3; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Unstimulated Treatment control marker detected.
Control Control GSM6030416 8808R2_213_IndexUDI0087_CTCACCAA+CTAGGCAA_L004_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D3; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: IgG1 isotype control Explicit characteristic control arm detected.
Control Control GSM6030417 8808R2_214_IndexUDI0088_TCTGTTGG+TCGAATGG_L004_001 RA-FLS and T-cells Fls donor: D2; Blood t-cell donor: D3; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: NANOBODY® isotype control Explicit characteristic control arm detected.
Untreated Control GSM6030425 8808R2_253_IndexUDI0003_GGACTTGG+CGCAGACG_L004_001 RA-FLS and T-cells Fls donor: D3; Blood t-cell donor: D3; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Unstimulated Treatment control marker detected.
Control Control GSM6030427 8808R2_255_IndexUDI0005_ATCCACTG+AGGTGCGT_L004_001 RA-FLS and T-cells Fls donor: D3; Blood t-cell donor: D3; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: IgG1 isotype control Explicit characteristic control arm detected.
Control Control GSM6030428 8808R2_256_IndexUDI0006_GCTTGTCA+GAACATAC_L004_001 RA-FLS and T-cells Fls donor: D3; Blood t-cell donor: D3; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: NANOBODY® isotype control Explicit characteristic control arm detected.
Untreated Control GSM6030436 8808R2_267_IndexUDI0017_TAATACAG+ATATTCAC_L004_001 RA-FLS and T-cells Fls donor: D3; Blood t-cell donor: D3; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: Unstimulated Treatment control marker detected.
Control Control GSM6030438 8808R2_269_IndexUDI0019_ATGTAAGT+ACTCTATG_L004_001 RA-FLS and T-cells Fls donor: D3; Blood t-cell donor: D3; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: IgG1 isotype control Explicit characteristic control arm detected.
Control Control GSM6030439 8808R2_270_IndexUDI0020_GCACGGAC+GTCTCGCA_L002_001 RA-FLS and T-cells Fls donor: D3; Blood t-cell donor: D3; Cell type: Fibroblast-like synoviocytes from rheumatoid arthritis (RA) donors cocultured with CD4 T cells from healthy donors; Treatment: NANOBODY® isotype control Explicit characteristic control arm detected.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.